BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT04468815
- Locations
- 🇺🇸
ICON (LPRA) - Salt Lake, Salt Lake City, Utah, United States
A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT04464577
- Locations
- 🇺🇸
Local Institution, Salt Lake City, Utah, United States
Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- Other: Placebo, Matching BMS-986331
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 48
- Registration Number
- NCT04444050
- Locations
- 🇺🇸
Local Institution - 0001, Anaheim, California, United States
🇺🇸ICON (LPRA) - Lenexa, Lenexa, Kansas, United States
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 44
- Registration Number
- NCT04349267
- Locations
- 🇺🇸
Local Institution - 0001, Germantown, Tennessee, United States
🇺🇸Local Institution - 0028, Sioux Falls, South Dakota, United States
🇨🇦Local Institution - 0013, Ottawa, Canada
A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
- Conditions
- HOCM, Hypertrophic Obstructive Cardiomyopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 112
- Registration Number
- NCT04349072
- Locations
- 🇺🇸
Local Institution, Houston, Texas, United States
🇺🇸Local Institution - 0015, Rochester, Minnesota, United States
🇺🇸Local Institution - 0002, Portland, Oregon, United States
A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer
- Conditions
- Cancer, Hepatocellular
- Interventions
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 26
- Registration Number
- NCT04340193
- Locations
- 🇺🇸
Local Institution - 0059, Louisville, Kentucky, United States
🇸🇬Local Institution - 0027, Singapore, Singapore
🇺🇸Local Institution - 0189, Coronado, California, United States
Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure
- Conditions
- Acute Decompensated Heart Failure
- Interventions
- Other: Placebo
- First Posted Date
- 2020-03-23
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT04318093
- Locations
- 🇦🇷
Local Institution - 0025, Cordoba, Argentina
🇦🇷Local Institution - 0009, Ciudad de Buenos Aires, Buenos Aires, Argentina
🇬🇷Local Institution - 0022, Athens, Greece
A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 21
- Registration Number
- NCT04311710
- Locations
- 🇳🇿
Local Institution - 0010, Auckland, New Zealand
🇺🇸Local Institution - 0013, Fort Wayne, Indiana, United States
🇮🇹Istituto Nazionale Tumori IRCCS Fondazione Pascale-s.c. melanoma, immunoterapia oncologica e terapie, Napoli, Italy
A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 403
- Registration Number
- NCT04308681
- Locations
- 🇨🇳
Local Institution - 0174, Taipei, Taiwan
🇨🇳Local Institution - 0175, Taipei, Taiwan
🇬🇧Local Institution - 0050, Cambridge, United Kingdom
A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult Participants
- Conditions
- Healthy Participants
- Interventions
- Drug: BMS-986165 Tablet formulation 1Drug: BMS-986165 Tablet formulation 2
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 40
- Registration Number
- NCT04305899
- Locations
- 🇺🇸
PRA Health Sciences - Lenexa, Lenexa, Kansas, United States